HFNC Treatment in COVID-19 Pneumonia

Completed

• Conditions: Coronavirus Infection; Pneumonia, Viral; Acute Respiratory Failure
• Interventions: Device: high flow nasal cannula device

• Registration Number: NCT04424836
• Lead Sponsor: Sisli Hamidiye Etfal Training and Research Hospital

Brief Summary

coronavirus disease 2019 related pneumonia is causing acute respiratory failure and this is the most common reason for ICU admission. We have several different way for respiratory support. HFNC is one of the new technics for oxygen support. Our main purpose to observe the effect of HFNC on coronavirus disease 2019 patients' ICU stay and mortality.

Detailed Description

In the first group (group H), the data of patients undergoing HFNC treatment, and in group II (Group K), the data of patients who received COT with a reservoir mask were included.

In HFNC support, the current air temperature is 31-37 degrees, the flow rate is 30-60 lt / min, and the FiO2 value is targeted so that saturation is 93% and above. Initially, continuous treatment was applied intermittently after the partial oxygen pressure / fraction of inspired oxygen(fio2) ratio exceeded 250 and clinical well-being occurred.

In patients in Group K, fingertip saturation was targeted as 93% and above, and a COT was applied with a reservoir mask with a flow rate of 6-15 l / min.

The flow rate was calculated using the formula of FiO2 (%) = 21 + 4 \* (liters / min) in patients undergoing COT. Noninvasive mechanical ventilation was applied to patients who could not be provided with adequate clinical and laboratory well-being in both groups (partial oxygen pressure / fraction of inspired oxygen ratio below 150) and invasive mechanical ventilation if this was insufficient.

Study Timeline

• Study Start: 2020-05-15
• Primary Completion: 2020-06-04
• Study Completion: 2020-06-05
• Study First Submitted: 2020-06-07
• Study First Submitted QC: 2020-06-08
• Study First Posted: 2020-06-11
• Status Verified: 2020-07
• Last Update Submitted: 2020-07-15
• Last Update Posted: 2020-07-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 43

Inclusion Criteria

• We include the patient with acute respiratory failure related coronavirus disease 2019 (diagnosed with polymerase Chain Reaction), older than 18 year and supported by High Flow Nasal cannulae or conventional oxygen treatment(COT).

Exclusion Criteria

• Patients with primary pulmonary disease, Glasgow Coma scale≤ 12 , respiratory acidosis in the first blood gases(ph≤ 7,2 - pCO2≥50) will exclude.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
H GROUP	high flow nasal cannula device	patients get the oxygen supply with high flow nasal cannula . In group H, HFNC device settings the initial flow rate was 30 L/min and could be increased to 60. The Fio2 was adjusted to maintain oxygen saturation as indicated by a pulse oximetry reading of grater than or equal to %90.

Primary Outcome Measures

Name	Time	Method
short term mortality	in 28 days.	the mortality rate of patients
icu stay	up to 28 days	means the stay day of patients in intensive care unit

Secondary Outcome Measures

Name	Time	Method
blood gases	at the admission time and 24th hour	partial oxygen pressure, partial carbon dioxide pressure . both measured in mmhg

Trial Locations

Locations (1)

Sisli Etfal Research and Training Hospital; 🇹🇷 Istanbul, Turkey